Introduction
All anaplastic or low-differentiated nasopharyngeal carcinomas (NPCs), irrespective of geographical or ethnic origin, carry multiple Epstein-Barr virus (EBV) genomes and express the gene for Epstein-Barr virus nuclear antigen (EBNA)-I (Klein et al., 1974; Andersson-Anvret et al., 1977) . The regularity of this association suggests that the virus plays a role in the development of these tumours. Due to insufficient knowledge about the interaction of the virus with the cells of the nasopharyngeal epithelium (Sixbey, 1989; Li et al., 1992) , the role of the virus in NPC is not understood.
In the carcinoma cells, EBV genomes are maintained in a state of latency. The major membrane protein, latent membrane protein (LMP)-I is expressed in approximately two-thirds of the NPC biopsies (Ffihraeus et al., 1988; Young et al., 1988) . We have previously found that LMP-l-negative NPCs carry methylated 5'-flanking (LRS) sequences, in contrast to LMP-1-positive tumours, where the same sequences are unmethylated (Hu et al., 1991 a) . This indicates that the lack of LMP-1 expression in the negative tumours is due to a regulatory change * Author for correspondence (mail should be sent to the Seattle address). Fax 1 206 667 5815. rather than to technical problems of protein detection in frozen tumour specimens. Earlier studies of EBV gene expression in NPC have established that, in addition to EBNA-1 and LMP-1, transcripts of LMP-2A and -2B, BZLF-1 and BARF-0 can be detected in NPC biopsies by cDNA-directed PCR (Brooks et al., 1992; Busson et al., 1992; Smith & Griffin, 1991; Gilligan et al., 1991) .
The LMP-1 and LMP-2B transcripts are expressed from separate promoters located close to the terminal repeats in the BamHI Nhet fragment at the right-end of the viral genome (Laux et al., 1988 (Laux et al., , 1989 Sample et al., 1989) . Expression of both genes is controlled by a shared bidirectional promoter region (LRS) in BamHI Nhet (Laux et al., 1989) . LMP-2A mRNA is initiated from a separate promoter close to the BamHI A/Nhet border and contains an additional coding 5' exon in comparison to LMP-2B (Sample et al., 1989) . The two LMP-2 transcripts co-terminate in the left-end of the viral DNA and can thus form only after circularization of the genome in the cell (Laux et al., 1988) .
The small biopsy samples usually available from NPC tumours and the limited number of tumours studied to date are causes for concern regarding the sensitivity of the assays and the influence of possible artifacts, in particular since the published studies (Brooks et al., 1992; Busson et al., 1992; Smith & Griffin, 1991; Gilligan et al., 1991) show significant differences in the detection of different genes. In the present study, we have 
Methods
Cells and tumour biopsies. CAO (Hu et al., 1991 b; Cao et al., 1987 ) and C15 (a gift from T. Tursz; Busson et al., 1988) are, respectively, Chinese and north African NPC tumours serially propagated in BALB/c nude mice. B95-8 is a line of marmoset B lymphocytes immortalized with an EBV type A virus from a mononucleosis case (Shope et al., 1973) .
P3HR-1 is a Burkitt's lymphoma (BL) line producing nontransforming EBV due to a deletion of the EBNA-2 gene (Bornkamm et al., 1982; Heston et al., 1982) . Namalwa is a BL line of African origin containing two closely located integrated copies of EBV (Henderson et al., 1983) . Rael is an EBNA-2-negative BL line (Klein et al., 1974) . FA is an EBV-negative B cell lymphoma line (DG75) transfected with an EBNA-2 expression plasmid (a kind gift from Dr L. Rymo, Gothenburg, Sweden). HL60 is a human promyelocytic leukaemia cell line (Collins et al., 1977) . Biopsies nos 2 to 35 were obtained from Chinese patients diagnosed with NPC in the Shanghai area in China. The specimens were snap-frozen in liquid nitrogen immediately after surgical removal and kept at -70 °C before use.
RNA extraction and cDNA synthesis. Total RNA was extracted from the tumour biopsies using guanidinium thiocyanate and acid phenol essentially as described by Chomczynski & Sacchi (1987) . First strand cDNA was made from 1-2 lag total RNA in a 20 I~l reaction mixture containing 50 mM-Tris-HC1, pH 8"5, 140 mM-KCI, 10 mM-MgC12, 4 mM-dithiothreitol, 1.25 mM of each dNTP, 1 ~tM cDNA primer of random 14-mers, 25 U placental RNase inhibitor (Boehringer) and 2(~30 U AMV reverse transciptase (Seikagaku America Inc.). Reaction mixtures were incubated for 60 min at 42 °C followed by 5 min at 95 °C. cDNA from a single reaction mixture was used for subsequent detection of LMP-1, LMP-2A and LMP-2B.
PCR. The reactions were performed in 50 ~1 volumes containing 5 lal of the cDNA reaction, 10 mM-Tris-HC1, pH 8.5, 40 mM-KC1 1-3 mMMgC12 (optimized for each primer pair), 50 ~tM of each dNTP, 1 laM primers (Table 1 ) and 15.5 U Taq polymerase (Amplitaq, PerkinElmer). For nested PCR, a 3 ~1 volume from the first reaction mixture was transferred to a new reaction mxiture where the inner primer pair was used. Amplifications were performed in Techne PHC-2 or PHC-3 thermocyclers using the cycling conditions listed in Table 2 . Annealing temperatures for the nested primers were chosen to avoid annealing of residual primers from the first round of PCR during the second round. 
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Amplification products were separated in agarose gels containing 0.8 1.5 % low melting point and 0'7 % regular agarose (Sigma). For single primer PCRs the specificity of PCR products was verified by membrane filter hybridization of the products to specific oligonucleotide probes labelled at their 5' ends using T4 polynucleotide kinase (Boehringer) and [7-3~P]ATP (Amersham). The sequences of internal probes used are listed in Table 1 .
Sensitivity assays. Total RNA from the Namalwa cell line (for testing the sensitivity of detection of EBNA-2 transcripts; see Fig. 4 ) was diluted in tenfold steps in water. Synthesis of cDNA was done by adding 5 gl aliquots of the diluted RNA containing from 2 ~tg to 2 pg of the EBV-containing RNA into each 20 I11 cDNA reaction mixture. After synthesis was complete, 5 gl of the cDNA reaction mixture was added to the subsequent PCR step.
Results

EBNA-1 transcription
Thirteen biopsies (nos 2, 3, 4, 6, 9, 10, 14, 15, 16, 19, 21, 28 and 31) were tested for BamHI-Q/U/K-spliced transcripts, encoding EBNA-1 only, using primers in BamHI Q and K for the PCR reaction, followed by hybridization of the amplified sequences to an oligonucleotide probe from BamHI U ( Table 1 ). All biopsies tested were positive for EBNA-1 transcripts (Fig. 1) . The same was true for the two nude-mouse-propagated NPC Nested amplification of cDNA from 0.5 pg total RNA from the two nude-mouse-propagated NPC tumours (C15 and CAO) and NPC biopsies nos 2, 3, 6, 10 and 31 using the 5' BamHI Y3 primer S.48400 and the 3' BamHI K primer A. 108171 in the first round, followed by a combination of 5' BamHI Q primer S. 67519 and 3' BamHI K primer A. 108065 for the second round (Table 1 ). The schematic transcription map outlines the structure of the Y3/U/K-spliced transcripts of EBNA-1, which originate at either the BarnHI C or the BamHI W promoter, and shows the location of the oligonucleotides used. The molecular size marker (left-hand lane) is a 1 kb ladder (Gibco-BRL), of which fragments of the following size are shown: 517, 507, 394, 344, 298, 220, 201, 154 and 142 bp. tumour lines, CAO and C15. In addition, five of the biopsies (nos 2, 3, 6, 10 and 31) and the tumour lines CAO and C15 were tested for EBNA-1-6 transcripts utilizing the Y3/U/K-spliced W-or C-derived messages, with negative results (Fig. 2) , as expected.
Absence of EBNA-2 transcripts
Ten biopsies (nos 4, 7, 13, 15, 21, 28, 30, 31, 34 and 35) and the two nude mouse tumours CAO and C15 were tested for EBNA-2 transcripts using nested primers in BamHI Y2 and YH (Table 1 ) and all were found to be (Table 1) were used to amplify cDNA from 0.5 ~tg total RNA from the 13 NPC biopsies shown and from the nude-mouse-propagated NPC tumours CI 5 and CAO. The primer A. 67539 (in BamHI U) was used as an internal probe. The schematic transcription map shows the approximate location of the oligonucleotides.
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EBNA-2 mRNA Y2 BYRF-1 267 bp Fig. 3 . Failure to detect EBNA2 transcripts. Nested amplification of cDNA corresponding to 0.5 lag total RNA from the cell lines FA, P3HR1 and Rael, the nude-mouse-propagated NPC tumours C15 and CAO and 10 NPC biopsies is shown. For the first round, the primers S.47911 and A.48589 were used and for the second round the primers S.47954 and A.48613 (Table 1 ). The approximate location of these primers is indicated in the accompanying transcription map. The size marker (left-hand lane) is the same as in Fig.  2 .
EBNA-2 mRNA
Y2
BYRF-1 Namalwa RNA 267 bp Fig. 4 . Sensitivity of detection of EBNA-2 transcripts. Nested PCR was used as described in Fig. 3 to detect EBNA-2 transcripts in total RNA from the Namalwa cell line. Tenfold dilutions of Namalwa RNA were made into a solution of total RNA from the EBVnegative cell line HL60. The total RNA concentration in the cDNA reactions was 100 lag/ml. For each PCR reaction, 5 lal of the cDNA reaction was used, containing a fraction of Namalwa cDNA corresponding to the amount of total Namalwa RNA indicated.
negative (Fig. 3 ). Using c D N A from the EBNA-2-expressing BL line Namalwa as a control, we established that EBNA-2 m R N A was easily detectable in c D N A synthesized from 0.5 pg total R N A from Namalwa cells under the experimental conditions used. The experiment shown in Fig. 4 corresponds to an input of c D N A from 0'5 lag total R N A from each sample of tumour or cell line shown.
LMP-1, LMP-2A and LMP-2B transcripts
The presence of transcripts of the three LMP genes in NPC biopsies and control cells is shown in Fig. 5 . Only the results after the second round of amplification are shown. Specific products were generally not visible after single round of P C R amplification. With respect to their expression of the LMP genes, the NPC biopsies may be arranged into three groups. In the first group (nos 2, 4, 6, 13, 14, 17, 19, 21, 25, 27, 28, 29, 30, 32, 33, 34 and 35) , all three LMP genes were expressed. In the second group (nos 7, 9, 10, 15 and 16), LMP-1 and LMP-2B were expressed, but LMP-2A transcripts were not detected and in the third group (nos 3 and 31), none of the LMP genes could be detected, although BamHI-FQ/U/Kspliced EBNA-1 transcripts were present (Fig. 5 , Table   3 ).
All 20 biopsies and the two N P C tumour lines CAO and C15 that expressed LMP-1 also expressed LMP-2B RNA. Neither LMP-1 nor LMP-2B were ever expressed singly. LMP-2A transcripts were detected in 17 of the biopsies and in the two N P C tumour lines, CAO and C15. All the LMP-2A-expressing tumours simultaneously expressed LMP-1 and LMP-2B. LMP-2A was not expressed in the absence of the two other genes. However, LMP-2A transcription did not totally correlate with the expression of the other two L M P genes; in five of the 22 biopsies expressing LMP-1 and LMP-2B (nos 7, 9, 10, 15 and 16), LMP-2A transcripts were not detected.
When tested under the same experimental conditions, two African BL biopsies, K M and RQ, failed to show expression of LMP-I, LMP-2A, LMP-2B or Y 3 / U / Kspliced EBNA-1 transcripts, although Q/U/K-spliced EBNA-1 transcripts were easily demonstrated using a single pair of primers and an internal oligonucleotide probe as for the N P C biopsies (data not shown).
Two biopsies (nos 3 and 31) expressed none of the tested viral genes except EBNA-1. This is likely to reflect a true absence of these transcripts in the cells rather than absence of intact R N A since EBNA-1 transcripts were demonstrated (Fig. 1, Table 3 ). As a further control of the quality of the R N A extracted from the biopsies, we amplified a 300 bp fragment spanning a splice junction in 
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570 bp Fig. 6 . Detection of transcripts for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in NPC biopsies. Seven NPC biopsies (nos 3, 7, 9, 10, 15, 16 and 31) that showed a discordant expression pattern of the LMP genes were tested to assess the integrity of the RNA. Using a single primer pair, cDNA for G A P D H was amplified to yield the predicted 570 bp fragment. The left-hand lane contains a size marker (as in Fig. 2) .
Discussion
EBV follows different programmes of viral gene expression in latently infected cells of different phenotypes. Three types of viral latency (latency I-III) have been identified based on the phenotype of the target cell, the expression of key viral genes and the choice of promoters for the expression of the EBNA genes (Kerr et al., 1992; Bornkamm et al., 1982 ; Table 4 ). The fact that viral gene expression is subject to differential control in different cell types is most clearly manifested in the expression of EBNA-1. This is the only virally encoded gene which is expressed in all known cell t The BamHI C-and W promoters utilize splicing between exons in BamHI Y 3 / U / K and the BamHI FQ promoter utilizes splicing between exons in BamHl Q / U / K to produce the EBNA-1 message. The Y3/U/K-spliced message occurs in cells where EBNA-1 coexists with EBNA-2-6 messages. EBNA-2 messages are produced either from a BamHI C-or a BamHI W-promoted message, which splices through exons in BamHI Y2 and YH. Splice junctions, joining the different exons in a particular m R N A are denoted by a / . Multiple exons in the same BamHI fragment are distinguished by a number added to the letter designating the corresponding BamHI restriction fragment (as in BamHI Y3). Exons containing a BamHI restriction site are denoted by two capital letters for the two adjoining restriction fragments (as in BamHI FQ or BamHI YH).
types carrying EBV DNA. However, the virus utilizes two alternate programmes for expressing EBNA-1. In immunoblasts (LCL and BL III, Table 4), the mRNA for EBNA-1 is spliced from a huge primary transcript, originating from the C or the alternate W promoter through the W1, W2, Y3 and U exons to the coding sequences in BamHI K (latency type III). The mRNAs for the remaining EBNA genes (EBNA-2-6), expressed in type III latency, also originate at the C or W promoters. In other cell types that express EBNA-1 but not EBNA-2-6, i.e. BL type I (latency I), NPC, HD and T cell lymphomas (latency II), and somatic hybrids between B and non-B cells, where the non-B phenotype dominates (Kerr et al., 1992) , the C and W promoters are silent, while a unique EBNA-1 message is generated from a promoter in BamHI FQ (Schaefer et al., 1991 ;  Fig. 1 , Table 4 ).
Our data show that EBNA-1 mRNA in the NPC biopsies and the tumour lines CAO and C 15 is initiated exclusively from the promoter in BamHI FQ. This is in line with previous studies (Brooks et al., 1992; Sample et al., 1992; Smith & Griffin, 1992; L.-F. Hu and others, unpublished) . Our results also show the absence of C/W promoter activity either by lack of the Y3/U/K-spliced C-or W-derived EBNA-1 message (five NPC biopsies and the CAO and C15 tumour lines, Table 3 ) or by the absence of Y2/YH-spliced EBNA-2 transcripts (ten biopsies and the CAO and C15 tumour lines, Table 3 ). Three biopsies (nos 2, 6 and 10) and the CAO and C15 tumour lines were previously tested for utilization of the C or W promoters using PCR primers in C and W and were found to be negative (Hu et al., 1994) .
The transcriptional regulation of LMP-1 expression appears to be subject to control by both cellular and viral factors that act in trans. In B cells with type III latency, the expression of EBNA-2 is required to override negative cellular control of LMP-1 (Ghosh & Kieff, 1990; Wang et al., 1990; Ffihraeus et al., 1993) and LMP-2A and -2B expression (Zimber-Strobl et al., 1991) , while in epithelial cells, the LMP-1 promoter is constitutively active (Ffihraeus et al., 1993) .
Previous studies (Brooks et al., 1992; Busson et al., 1992; Smith & Griffin, 1991 have shown expression of the three LMP genes in NPC; however, the transcripts were detected at different frequencies in the different studies. In the present study, we attempted to increase the sensitivity of the PCR to circumvent the difficulties involved in obtaining quantitative yields of RNA from the frozen biopsy specimens. In order to estimate the sensitivity of the nested PCR used in this study to detect transcripts of the EBV genes studied, we have conducted specific assays, as shown in Fig. 4 . We show that when using nested PCR, the limiting amount of cDNA needed for detection of EBNA-2 mRNA corresponds to less than 0'5 pg total RNA, while our normal samples contain the equivalent of 0.5 ~g total RNA. The nested PCR assays for the LMP genes show similar levels of sensitivity (data not shown).
Our results show that it is possible to demonstrate LMP-1 RNAs in almost all NPC biopsies (over 90%), while LMP-1 protein is not detectable in more than about 65% of NPC biopsies (Ffihraeus et al., 1988; Young et al., 1988) . The more sensitive nested PCR assay used for detecting LMP gene transcripts also revealed a complete correlation between the presence of LMP-1 and LMP-2B transcripts in the turnouts. This correlation has not previously been reported in studies of in vivo material, but may reflect the fact that the transcription control region shared between LMP-1 and LMP-2B acts in a bidirectional fashion in NPC. This is in line with previous studies using reporter gene assays in cultured cells (Zimber-Strobl et al., 1991) . The strict correlation between LMP-1 and LMP-2B transcription is not shared by LMP-2A, since five of the 22 biopsies expressing LMP-1 and LMP-2B lacked LMP-2A transcripts.
Of the 24 turnouts tested (including the CAO and C15 tumour lines), 17 expressed all three LMP genes in addition to the seemingly obligate expression of EBNA-1. Does this set of viral genes constitute the basic gene expression repertoire of EBV in all cell types of latency II? The test of this postulate must await additional studies of HD cells and T cell lymphomas.
The presence in our material of two biopsies (nos 3 and 31) expressing only EBNA-1 is puzzling. It could be the result of an artefact, but could also be an indication that latency I occurs in NPC, albeit at a low frequency.
